The agreement between the Abu Dhabi-based entities, sovereign wealth fund, Mubadala Investment Company, and AI and cloud computing specialist, G42, is aimed at bolstering biopharma linked innovation, R&D and manufacturing capabilities in the region.
Australia company, Inventia Life Science, which is focused on advanced 3D cell cultures for research and clinical purposes, has just closed a US$25M Series B funding round, led by Blackbird Ventures.
SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).